Biocept reports first quarter 2023 financial results

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended march 31, 2023 and provides a business update. “i'm exceptionally pleased with the progress being made with our foresee clinical trial, which is specifically designed to generate evidence of cnside™'s clinical utility to support adoption into clinical care guidelines and further broaden physician use. trial enrol.
BIOC Ratings Summary
BIOC Quant Ranking